Antimuscarinic agents8 (oxybutynin, tolterodine, darifenacin, solifenacin, fesoterodine, and trospium) increased continence rates and improved UI. Consider ADR9 risk vs severity/bothersomeness of UI

By rray, 24 December, 2014

Detail (Long)

Antimuscarinic agents<sup>8</sup> (oxybutynin, tolterodine, darifenacin, solifenacin, fesoterodine, and trospium) increased continence rates and improved UI. Consider ADR<sup>9</sup> risk vs severity/bothersomeness of UI